… established “trial and error” method of treatment and instead … -function CYP2C19 on ticagrelor plus aspirin when … migraine medication, and CYP enzymes metabolize migraine drugs. Robust … continuous monitoring and personalized treatments; advanced neuroimaging to …

… Acute Myocardial Infarction) randomized clinical trial. Data were collected from … percutaneous coronary intervention. The trial compared the active control and … .61916 Keywords: De-escalation, Strategy, Ticagrelor, Clopidogrel, AMI, Patients, improves, …

… trials shaping the future of cardiovascular medicine … trial enrolled 205 patients receiving moderate- or high-intensity statins … trial demonstrated that bentracimab, an investigational reversal agent for ticagrelor … diagnostic and treatment challenges clinicians …

… Scienza, Turin, Italy 2Department of Medical Sciences, University of Turin, Turin … step forward in de-escalating treatment The evolution of dual antiplatelet … a potent P2Y12 inhibitor—typically ticagrelor, as supported by available evidence …

… antiplatelet agent ticagrelor safely and effectively reversed ticagrelor… Professor of Cardiovascular Medicine at the Icahn School … from the trial because of treatment-related adverse drug reactions, … was funded by PhaseBio Pharmaceuticals, Inc., and SFJ …

… bleeding complications linked to ticagrelor, a common drug used to treat patients … center international clinical trial analyzing bentracimab, the first experimental treatment of its … Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of …

… trial suggest bentracimab, a drug designed to reverse ticagrelor’ … Professor of Cardiovascular Medicine at the Icahn School … Pharmaceuticals, an application for bentracimab was submitted to the FDA … group experienced serious treatment-related adverse events …

… for patients on ticagrelor requiring urgent surgery … Professor of Cardiovascular Medicine at the Icahn … Pharmaceuticals, bentracimab is under review by the US Food and Drug Administration (FDA … patients experienced serious treatment-related adverse events, …

… phase 3 REVERSE-IT trial. Presented at the … the FDA did grant bentracimab orphan drug designation.” Ticagrelor is commonly … or treatment discontinuations due to the study drug. According … by bentracimab developers PhaseBio Pharmaceuticals and SFJ Pharma, the …

… a drug developed as an antidote to the antiplatelet agent ticagrelor (Brilinta … ; AstraZeneca) safely and effectively reversed ticagrelor’s antiplatelet effects in patients … withdrew from the trial because of treatment-related adverse drug reactions.1,2 …